Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. April 2020 08:00 ET | Quelle: Oncology Pharma, Inc.

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of...
30. September 2019 06:30 ET | Quelle: Oncology Pharma, Inc.

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments

SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction...
19. August 2019 08:00 ET | Quelle: Oncology Pharma, Inc.

Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ)...